Sugi Predict

Sugi Predict / Compounds / SCHEMBL12116425

SCHEMBL12116425

SCHEMBL12116425

O=C1CCc2ccc(OCCCCc3nnnn3C3CCCCC3)cc2N1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 5/20 0.86
▸ PDE3A Q14432 5/20 0.86
▸ MEN1 O00255 1/20 0.86
▸ ABCC4 O15439 1/20 0.86
▸ CACNA1F O60840 1/20 0.86
▸ ABCB11 O95342 1/20 0.86
▸ ALDH1A1 P00352 1/20 0.86
▸ LMNA P02545 1/20 0.86
▸ CYP1A2 P05177 1/20 0.86
▸ CYP3A4 P08684 1/20 0.86
▸ ADORA3 P0DMS8 1/20 0.86
▸ CYP2C9 P11712 1/20 0.86
▸ TSHR P16473 1/20 0.86
▸ MAPK1 P28482 1/20 0.86
▸ THPO P40225 1/20 0.86
▸ OPRK1 P41145 1/20 0.86
▸ BLM P54132 1/20 0.86
▸ PMP22 Q01453 1/20 0.86
▸ CACNA1D Q01668 1/20 0.86
▸ KMT2A Q03164 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7318751 0.97 PDE3B (0.81) PDE3BPDE3AMEN1ABCC4CACNA1F
Cilostazol SCHEMBL16128 0.93 PDE3B (1.00) PDE3BPDE3AMEN1ABCC4CACNA1F
Cilostazol SCHEMBL29389547 0.93 PDE3B (1.00) PDE3BPDE3AMEN1ABCC4CACNA1F
Cilostazol SCHEMBL1818013 0.93 PDE3B (1.00) PDE3BPDE3AMEN1ABCC4CACNA1F
SCHEMBL7307973 0.90 PDE3B (0.94) PDE3BPDE3AMEN1ABCC4CACNA1F
Cilostazol SCHEMBL5798390 0.89 PDE3B (0.93) PDE3BPDE3AMEN1ABCC4CACNA1F
SCHEMBL12117982 0.89 PDE3B (0.69) PDE3BPDE3AMEN1ABCC4CACNA1F
Cilostazol SCHEMBL5798394 0.89 PDE3B (0.92) PDE3BPDE3AMEN1ABCC4CACNA1F
SCHEMBL9368060 0.85 PDE3B (0.74) PDE3BPDE3AMEN1ABCC4CACNA1F
Cilostazol SCHEMBL825668 0.84 PDE3B (0.82) PDE3BPDE3AMEN1ABCC4CACNA1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10011569-B2 Process for synthesizing oxidized lactam compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2018-07-03 — — US disclosed
US-10011569-B2 Process for synthesizing oxidized lactam compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2018-07-03 — — US disclosed
US-20170267639-A1 Process for Synthesizing Oxidized Lactam Compounds JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2017-09-21 — — US disclosed
US-20170267639-A1 Process for Synthesizing Oxidized Lactam Compounds JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2017-09-21 — — US disclosed
US-9650341-B2 Process for synthesizing oxidized lactam compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2017-05-16 — — US disclosed
US-9650341-B2 Process for synthesizing oxidized lactam compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2017-05-16 — — US disclosed
US-20160024012-A1 Process for Synthesizing Oxidized Lactam Compounds JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2016-01-28 — — US disclosed
US-20160024012-A1 Process for Synthesizing Oxidized Lactam Compounds JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2016-01-28 — — US disclosed
US-9126936-B2 Process for synthesizing oxidized lactam compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2015-09-08 — — US disclosed
US-9126936-B2 Process for synthesizing oxidized lactam compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2015-09-08 — — US disclosed
US-20140051852-A1 Process for Synthesizing Oxidized Lactam Compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2014-02-20 — — US disclosed
US-20140051852-A1 Process for Synthesizing Oxidized Lactam Compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2014-02-20 — — US disclosed
US-8536328-B2 Process for synthesizing oxidized lactam compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2013-09-17 — — US disclosed
WO-2011140183-A1 PROCESS FOR SYNTHESIZING OXIDIZED LACTAM COMPOUNDS ALKERMES, INC. (US) 2011-11-10 — — WO disclosed
US-20110275803-A1 PROCESS FOR SYNTHESIZING OXIDIZED LACTAM COMPOUNDS ALKERMES, INC. (US) 2011-11-10 — — US disclosed
US-20110275803-A1 PROCESS FOR SYNTHESIZING OXIDIZED LACTAM COMPOUNDS ALKERMES, INC. (US) 2011-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267639-A1 Process for Synthesizing Oxidized Lactam Compounds COASY, DHPS, OXA1L PDE3B 1244/4885PDE3A 1983/4885MEN1 1579/4885
US-10011569-B2 Process for synthesizing oxidized lactam compounds COASY, DHPS, OXA1L PDE3B 1244/4885PDE3A 1983/4885MEN1 1579/4885
US-20140051852-A1 Process for Synthesizing Oxidized Lactam Compounds COASY, DHPS, OXA1L PDE3B 1244/4885PDE3A 1983/4885MEN1 1579/4885
US-20160024012-A1 Process for Synthesizing Oxidized Lactam Compounds COASY, DHPS, OXA1L PDE3B 1244/4885PDE3A 1983/4885MEN1 1579/4885
US-20110275803-A1 PROCESS FOR SYNTHESIZING OXIDIZED LACTAM COMPOUNDS COASY, DHPS, OXA1L PDE3B 1244/4885PDE3A 1983/4885MEN1 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.